Fig. 1: TCR-mediated, rapid Met consumption governs T cell effector function.

a,b, Quantification of intracellular amino acids at 10 min (a) and SAM and SAH up to 60 min (b) in OT-I T cells activated with 10 ng ml⁻¹ SIINFEKL (n = 3 biological replicates). c, T cell proliferation by means of cell-trace violet staining of OT-I CD8⁺ T cells activated in either 0.1 mM Met or 0.03 mM Met for the times indicated before restoration to 0.1 mM Met in 0.03 mM Met conditions and then analyzed 72 h postactivation. Representative of three biological replicates per group. d, Schematic design for OT-I T cell activation initially in 0.1 or 0.03 mM Met, followed by restoration of Met to 0.1 mM for 24 h before injection into B16-OVA tumor-bearing mice. e, Tumor growth of B16-OVA in Rag1^−/− treated with OT-I CD8⁺ T cells activated as described in d for 30 min–6 h (n = 5 mice per group). f,g, Tumor growth (f) and survival (g) of B16-OVA tumors in Rag1^−/− mice after transfer of 24-h-activated OT-I T cells with first 30 min of stimulation being in 0.1 or 0.03 mM Met with 2.5 ng ml⁻¹ SIINFEKL before restoration to 0.1 mM Met (n = 5 mice per group). h,i, Tumor growth (h) and survival (i) of B16-OVA tumors treated with activated GP33⁺-memory T cells as described in Extended Data Fig. 1d (n = 5 mice per group). Data are mean ± s.d. Paired two-tailed Student’s t-test (a), unpaired one-tailed Student’s t-test (b), two-way ANOVA (e, f, h) and Mantel–Cox log rank test (g, i). Illustrations in d created with BioRender.com.

Source data